|
|||||||||||||||||||
Leadership: |
Principal Investigator | ||||||||||||||||||
Primary Activity Coordinators: |
Research Research Director |
||||||||||||||||||
Discipline Coordinators: |
Genetics Pediatrics: Developmental/Neonatology Psychiatry: Developmental |
||||||||||||||||||
Specialty Resource Contacts: | Director of the Fragile X Treatment and Research Center | ||||||||||||||||||
Discipline(s): |
Medicine-Pediatrics Medicine-Developmental-Behavioral Pediatrics |
||||||||||||||||||
Research: | Fragile X syndrome, premutation disorders including FXTAS, targeted treatment studies | ||||||||||||||||||
Education: | MD from Stanford Medical School
Pediatric Residency at Stanford and also at University of San Diego Fellowship in Developmental and Behavioral Pediatrics university of California San Diego | ||||||||||||||||||
Service: | University of Colorado Director of Child Development Unit at Children's Hospital 1980-2000
Medical Director of the MIND Institute at Univ of California Davis 2000-2023 |
Vita/Bio
Dr. Randi Hagerman is a developmental and behavioral pediatrician and a Distinguished Professor of Pediatrics at the MIND Institute at UC Davis. She is internationally recognized as both a clinician and researcher in the field of neurodevelopmental disorders including autism and fragile X syndrome. Dr. Hagerman received her M.D. from Stanford University, where she also carried out her Pediatric residency. She completed a Fellowship in Learning and Disabilities and Ambulatory Pediatrics at UC San Diego, then led Developmental and Behavioral Pediatrics at the University of Colorado for 20 years. She co-founded the National Fragile X Foundation in 1984. In 2000, Hagerman joined the MIND Institute and she carries out treatment trials for Fragile X syndrome, ASD and FXTAS. There, she and her team discovered the Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), a neurodegenerative disorder associated with the fragile X premutation.
Hagerman has written over 500 peer-reviewed articles and numerous book chapters on neurodevelopmental disorders, as well as editing several books on fragile X disorders including a 2020 book edited by Hagerman and Hagerman titled Fragile X Syndrome and Premutation Disorders published by MacKeith press and she coedited the second edition of the Textbook of Autism Spectrum Disorders published by the American Psychiatric Publishing in 2023. Her research includes targeted treatment trials for Fragile X syndrome, autism, FXTAS and other premutation disorders.